|
Factors associated with better overall survival (OS) in patients with previously treated, PD-L1–expressing, advanced NSCLC: Multivariate analysis of KEYNOTE-010. |
|
|
Consulting or Advisory Role - AstraZeneca; Genentech/Roche; Lilly; Merck; Pfizer |
Research Funding - Genentech; Merck |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; Verastem |
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst) |
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst) |
Travel, Accommodations, Expenses - Merck Sharp & Dohme |
Other Relationship - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Roche |
Speakers' Bureau - Bristol-Myers Squibb; Roche |
Research Funding - Merck; Roche |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Roche (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie; Abbvie (I); AstraZeneca; Bristol-Myers Squibb; Celgene; Genentech |
Speakers' Bureau - Celgene; Genentech; Merck |
|
|
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Eurofarma; Pfizer; Teva |
Speakers' Bureau - AstraZeneca; Bayer; Eurofarma; Lilly; Merck Serono; MSD; Novartis; Roche |
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Boehringer Ingelheim; Eurofarma; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche |
|
|
Consulting or Advisory Role - Lilly; Merck Sharp & Dohme |
|
|
|
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst) |